KOL to sell Neoprobe gamma detection systems:
This article was originally published in Clinica
KOL Bio-Medical is to distribute Neoprobe's current and future gamma-guided surgery products in the US under a multi-year agreement. Chantilly, Virginia-based KOL's 60 sales representatives will sell the Neoprobe 1500 and neo2000 gamma detection systems, which are used for intraoperative lymphatic mapping procedures for breast cancer and melanoma. The agreement with KOL replaces one held with Ethicon Endo-Surgery, which was terminated by Dublin, Ohio-based Neoprobe.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.